학술논문
Ventricular Arrhythmias and Hemodynamic Collapse During Acute Coronary Syndrome- Increased Risk for Sudden Cardiac Death?
Document Type
Academic Journal
Author
Järvensivu-Koivunen M; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Tynkkynen J; Department of Radiology, Tampere University Hospital, Tampere, Finland.; Oksala N; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Vascular Centre, Tampere University Hospital, Tampere, Finland.; Finnish Cardiovascular Research Center Tampere.; Eskola M; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Heart Hospital, Tampere University Hospital, Tampere, Finland.; Hernesniemi J; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Finnish Cardiovascular Research Center Tampere.; Heart Hospital, Tampere University Hospital, Tampere, Finland.
Source
Publisher: Oxford University Press Country of Publication: England NLM ID: 101564430 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-4881 (Electronic) Linking ISSN: 20474873 NLM ISO Abbreviation: Eur J Prev Cardiol Subsets: MEDLINE
Subject
Language
English
Abstract
Aim: In acute phase of acute coronary syndrome (ACS), ventricular tachycardia (VT) and/or ventricular fibrillation (VF) leading to resuscitation are not considered to be associated with increased long-term sudden cardiac death (SCD) because the cause - acute ischemia - is believed to be reversible.Aim of this study was to investigate whether ventricular arrhythmias leading to sudden cardiac arrest during ACS associate with the risk of incident SCD in patients with normal or mildly impaired left ventricular ejection fraction (LVEF).
Methods: This study is based on a retrospective analysis of all 8,062 consecutive ACS patients undergoing coronary angiography with baseline LVEF ≥40% between 2007-2018 (follow-up until December 31st, 2021). The primary outcome was SCD equivalent life-threatening ventricular arrhythmias (LTVA) composing of true SCDs, aborted SCDs by successful resuscitation or appropriate ICD therapy. The risk of sudden LTVA was estimated with multivariate subdistribution hazard model using other deaths as competing events.
Results: Two-hundred and thirteen (n=211, 2.6%) patients suffered acute phase VF/VT leading to resuscitation and survived to discharge and most happened before angiography (80.6%, N=170) and were VF (92.9%, N=196). During a median follow-up of 7.6 years, 3.9% (N=316) of all the patients had LTVA (10.0% in VF/VT group vs 3.8% in other patients). VF/VTs during ACS associated with an increased risk for future SCD (HR 3.07; 95% CI 1.94-4.85, p<0.001). Most LTVAs occurred in patients without ICDs.
Conclusions: VF/VT in ACS associates with remarkably high long-term risk for SCD in patients with LVEF ≥40%.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Methods: This study is based on a retrospective analysis of all 8,062 consecutive ACS patients undergoing coronary angiography with baseline LVEF ≥40% between 2007-2018 (follow-up until December 31st, 2021). The primary outcome was SCD equivalent life-threatening ventricular arrhythmias (LTVA) composing of true SCDs, aborted SCDs by successful resuscitation or appropriate ICD therapy. The risk of sudden LTVA was estimated with multivariate subdistribution hazard model using other deaths as competing events.
Results: Two-hundred and thirteen (n=211, 2.6%) patients suffered acute phase VF/VT leading to resuscitation and survived to discharge and most happened before angiography (80.6%, N=170) and were VF (92.9%, N=196). During a median follow-up of 7.6 years, 3.9% (N=316) of all the patients had LTVA (10.0% in VF/VT group vs 3.8% in other patients). VF/VTs during ACS associated with an increased risk for future SCD (HR 3.07; 95% CI 1.94-4.85, p<0.001). Most LTVAs occurred in patients without ICDs.
Conclusions: VF/VT in ACS associates with remarkably high long-term risk for SCD in patients with LVEF ≥40%.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)